Troy Wilson

Dr. Troy E.
Wilson is an Executive Chairman at Abintus Bio, Inc. and an Independent Director at Puma Biotechnology, Inc. He is on the Board of Directors at Atrium Therapeutics, Inc., Puma Biotechnology, Inc., Cartography Biosciences, Inc., Cipher Genetics, Inc. and Montara Therapeutics, Inc. Dr. Wilson was previously employed as a Chairman, President & Chief Executive Officer by Zeta Acquisition Corp.
III, a Chairman, President, Chief Executive Officer & CFO by Kura Oncology, Inc., an Independent Director by Zosano Pharma Corp., a Non-Executive Chairman by Avidity Biosciences, Inc., an Executive Chairman by Wellspring Biosciences LLC, a Founding Partner by Presidio Partners, an Executive Chairman by Araxes Pharma LLC, a President, Chief Executive Officer & Director by Intellikine, Inc., a Chief Business Officer by Ambrx, Inc., a Vice President-Business Development by Novartis Institute for Functional Genomics, Inc., a Chief Executive Officer by Takeda Pharmaceuticals U.S.A., Inc., and a President by Wildcat Discovery Technologies, Inc. He also served on the board at ZP Opco, Inc. He received his undergraduate degree from the University of California, Berkeley, a graduate degree from New York University and a doctorate degree from the University of California, Berkeley.